Overview
Mycoplasma genitalium is a sexually transmitted infection contributing to 10-35% of non-chlamydial non-gonococcal urethritis in men and 10-25% of cervicitis and pelvic inflammatory disease in women 1.Diagnosis
Symptoms: Asymptomatic infections common; men present with urethritis, dysuria, discharge; women with vaginal discharge, dysuria, or PID symptoms 1.
Testing: Nucleic acid amplification testing (NAAT) required; must include macrolide resistance mutation investigation 1.Management
First-line Treatment: Azithromycin (cure rate 85-95% in susceptible infections); extended course may improve efficacy 1.
Adjunctive Therapy: Pre-treatment with doxycycline (30-40% cure rate) may reduce organism load and macrolide resistance risk 1.
Second-line Therapy: Moxifloxacin for resistant cases 1.Special Populations
Pregnancy: Specific recommendations not detailed in provided abstracts 1.
Pediatrics: Not addressed in provided abstracts 1.
Elderly: Not addressed in provided abstracts 1.
Comorbidities: No specific guidance provided for patients with comorbidities 1.Key Recommendations
Diagnose M. genitalium using nucleic acid amplification testing, including macrolide resistance mutation detection (Evidence: Strong 1).
Initiate treatment with azithromycin for susceptible infections; consider extended courses for improved efficacy (Evidence: Moderate 1).
Use doxycycline pre-treatment to potentially reduce organism load and minimize macrolide resistance development (Evidence: Moderate 1).References
1 Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. 2021 European guideline on the management of Mycoplasma genitalium infections. Journal of the European Academy of Dermatology and Venereology : JEADV 2022. link